1. Pink Sheet

Quizartinib Looks Like A Good Drug, ODAC Says, But Needs Another Efficacy Trial Before Approval

 
• By Michael Cipriano

US FDA's Oncologic Drugs Advisory Committee voted 8-3 against approval for Daiichi's quizartinib, although panelists felt the acute myeloid leukemia candidate would be approvable with another trial to better characterize its efficacy.

The US Food and Drug Administration's Oncologic Drugs Advisory Committee (ODAC) felt that Daiichi Sankyo Co. Ltd.'s acute myeloid leukemia candidate quizartinib is not quite ready for market in voting against approval by an 8-3 margin at a 14 May meeting. But panelists felt there is a path forward for the drug if the sponsor can more adequately define its efficacy in another trial.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from US FDA Performance Tracker

More from Regulatory Trackers